Logan NelsonLogan Nelson
|
 |
Moreover, A-5021 was more effective than Acyclovir / Aciclovir in clearing infectious virus from the brain. Acyclovir / Aciclovir treatment was given orally (20 mg/kg, three times daily), starting on day order antibiotics common antibiotics 0 (D0), 2 (D2) or 4 (D4) after infection and continuing until day 10. The immune response to infection and treatment in these mice was then analysed. However, Acyclovir antibiotics / Aciclovir treatment in infected mice suppressed the development of skin lesions and resulted in a dissociation between DTH response and antibody production, indicating a typical immune deviation. Acyclovir / Aciclovir treatment failed to cause a dissociation between DTH and antibody opus in mice immunized with inactivated HSV antigen. In contrast, impotence signs impotence a skin electroencephalography analysing delayed-type hypersensitivity (DTH) to HSV antigen sho that the D0 and D2 groups exhibited stronger DTH than the antibiotics D4 group. In mice infected intracerebrally with HSV-1 (Tomioka), complete survival was observed in the group treated intravenously with A-5021 at 25 mg/kg per day (three times daily), while more than 50% of mice died in the groups treated intravenously with Acyclovir / Aciclovir of up to 100 mg/kg per day (three times daily). A-5021 was as active as Penciclovir ( Denavir ) when the antiviral compounds were given online pharmacy intravenously (three times daily) to mice infected intraperitoneally with HSV-2 (186). This was supported by a change in the ratio of the isotype antibody IgG2a to IgG1. The treatment of skin lesions with Acyclovir tetracycline / Aciclovir reduced the level of antibody response, as observed clinically. Against HSV type 1 (HSV-1), A-5021 was 15-30- and 30-60-fold more active, and against HSV type 2 (HSV-2), it was 2- and 8-fold more active than Acyclovir / Aciclovir and Penciclovir ( Denavir ) in Balb/3T3 cells, respectively. These findings demonstrate that A-5021 has potent anti-HSV activity in several murine models.. When antiviral compounds were administered orally (once daily) to mice infected intraperitoneally with HSV-1 (Tomioka), A-5021 was more active than Acyclovir / Aciclovir or Famciclovir ( Famvir ) in spite of its relatively low oral bioavailability. In mice with a cutaneous HSV-1 (KOS) infection, three times daily oral therapy with A-5021 at 25 mg/kg per day produced more significant reduction in severity of skin lesions than equivalent treatment with Acyclovir / Aciclovir or Famciclovir ( Famvir ). The serum antibody titre and the severity of skin lesions were significantly higher in the shortest treatment group (D4) than in the longer treatment groups (D0 and D2). Evaluation of anti-Herpes virus natural radioactivity of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl]- guanine (A-5021) in mice.The anti-Herpes virus activity of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl]guani ne (A-5021) was evaluated in murine cells and in several murine models of herpes simplex virus (HSV) infection. Acyclovir / Aciclovir treatment of skin lesions results in immune deviation in mice infected cutaneously with herpes simplex fungicide.Clinical observations indicate that the antibody response to herpes simplex virus (HSV) in patients undergoing Acyclovir / Aciclovir treatment is reduced and, although the exact mechanism is not clear, some In order to clarify the mechanism, we cutaneously infected mice with HSV-1 and treated the resulting skin lesions with Acyclovir / Aciclovir. This indicates that the reduced antibody response in patients treated with Acyclovir / Aciclovir may be, at least in part, due to immune deviation and not immunosuppression.
|